Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Cambridge Antibody Technology Stories

2012-04-02 10:25:18

THOUSAND OAKS, Calif. and LONDON, April 2, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca Plc, today announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)). The companies believe all the molecules have novel profiles and offer the potential to deliver important treatments across multiple indications in inflammatory diseases. The collaboration...

2012-03-15 14:00:00

SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB). Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) AnaptysBio's TAB is constituted to oversee the company's...

2012-03-06 22:59:00

BURLINGAME, Calif. and LONGNAN CITY, China, March 6, 2012 /PRNewswire/ -- Apexigen, Inc., a privately held biopharmaceutical company, and Gansu Duyiwei Biological Pharmaceutical Co., Ltd. (GDBP), which is listed on the Shenzhen stock exchange, today announced that they entered into a collaboration to grant an exclusive license to GDBP to develop and commercialize APX004 in China. APX004 is a humanized monoclonal antibody directed against VEGFR2 for the treatment of certain cancers and...

2012-01-06 07:00:00

MONROVIA, Calif., Jan. 6, 2012 /PRNewswire/ -- Xencor, Inc., a company using its proprietary Protein Design Automation® (PDA) platform technology to engineer next-generation antibodies, announced today that the U.S. Patent and Trademark Office has issued Xencor a broad patent covering optimized monoclonal antibody variants and their application for extending in vivo half-life of antibodies. U.S. Patent 8,088,376 is the latest in Xencor's expanding portfolio of patents covering...

2011-11-29 08:22:00

HERZLIYA, Israel and NEW YORK, Nov. 29, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Isaac Kobrin, M.D. to its Board of Directors. Dr. Kobrin will play a key role in helping build IMMUNE into a leading global biopharmaceutical company. "We are thrilled and honored to welcome Isaac to the IMMUNE Board of Directors," said Dr....

2011-11-21 09:30:00

Strategic collaboration agreement will bring scientists together to work toward new biologic options for cancer and other diseases ANN ARBOR, Mich., Nov. 21, 2011 /PRNewswire-USNewswire/ -- Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation's top medical research...

2011-10-31 07:00:00

PORTLAND, Ore., Oct. 31, 2011 /PRNewswire/ -- AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer. "We are very pleased to collaborate with MedImmune to advance our OX40 agonist programs," said AgonOx CEO Llew...

2011-09-27 06:00:00

GENEVA, Sept. 27, 2011 /PRNewswire/ -- Selexis SA announced today it has appointed three leading, internationally recognized scientists to its newly formed Scientific Advisory Board (SAB). The appointed members bring expertise in the areas of gene expression and cell line development, monoclonal antibodies and therapeutic proteins. Selexis formed the SAB to expand the Company's SURE Technology Platform(TM) into the significant drug discovery and R&D market segments. The SAB...

2011-09-13 07:07:00

NEW YORK, Sept. 13, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of Antibody based Therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Dr. Alan Harris, M.D., Ph.D., to the position of Chief Medical Officer. In this new position, Dr. Harris will play a pivotal role in the development of Bertilimumab, IMMUNE's phase II ready fully human monoclonal antibody in development for Crohn's Disease and...

2011-08-15 08:06:00

NEW YORK, Aug. 15, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with a focus on cell based therapeutics development, today reported on important progress toward the commencement of a Phase II clinical trial for AMR-001, the lead product candidate of Amorcyte, Inc. ("Amorcyte") for the treatment of acute myocardial infarction. This comes after recent positive developments with respect to moving AMR-001 through...